BGM BGM Group Ltd. Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1779578 · Fiscal year ends 09/30
Financial factors as of 2025-09-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY51.1%
TTM net income YoY-1,282.1%
TTM EPS YoY10.0%
Revenue 3-yr CAGR-16.4%
Net income 3-yr CAGR—
Margins
Gross margin16.6%
Operating margin-33.2%
Net margin-52.6%
FCF margin-10.4%
EBITDA margin-29.3%
Returns
ROE-9.2%
ROA-8.2%
ROIC (approx.)-4.8%
Asset turnover0.16x
Leverage & solvency
Liabilities / assets9.7%
Debt / equity0.00x
Current ratio1.24x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.12x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue4.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | $37.92M | $25.10M |
| Cost of revenue | $31.61M | $20.98M |
| Gross profit | $6.31M | $4.11M |
| R&D expense | $672,669 | $1.36M |
| SG&A expense | $18.22M | $3.32M |
| Operating income | -$12.58M | -$563,771 |
| Pretax income | -$19.94M | -$2.14M |
| Income tax | $277,790 | -$619,981 |
| Net income | -$19.94M | -$1.44M |
| EBITDA | -$11.12M | $673,458 |
| EPS (basic) | -0.18 | -0.20 |
| EPS (diluted) | -0.18 | -0.20 |
| Weighted avg. shares (diluted) | 113.26M | 7.23M |
| Balance sheet | ||
| Cash & equivalents | $9.82M | $9.82M |
| Receivables | $4.25M | $1.54M |
| Inventory | $20.10M | $5.05M |
| Current assets | $51.55M | $29.77M |
| Goodwill | $350.85M | — |
| Intangibles | $4.49M | $4.54M |
| Total assets | $433.81M | $53.00M |
| Current liabilities | $41.60M | $8.78M |
| Total liabilities | $41.92M | $8.91M |
| Shareholders' equity | $390.88M | $42.74M |
| Shares outstanding | 200.62M | 7.23M |
| Cash flow statement | ||
| Operating cash flow | -$2.37M | $544,238 |
| Capital expenditure | $1.57M | $240,133 |
| Free cash flow | -$3.94M | $304,105 |
| Investing cash flow | -$162,908 | $983,418 |
| Financing cash flow | $2.62M | -$491,728 |
| Depreciation & amortization | $1.46M | $1.24M |
| Stock-based compensation | $10.23M | — |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.